



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Bernard Vanhove  
✉ [bernard.vanhove44@gmail.com](mailto:bernard.vanhove44@gmail.com)  
Odile Duvaux  
✉ [odile.duvaux@xenothera.com](mailto:odile.duvaux@xenothera.com)

<sup>†</sup>These authors share first authorship

<sup>‡</sup>These authors have contributed equally to this work

RECEIVED 19 April 2023  
ACCEPTED 20 April 2023  
PUBLISHED 28 April 2023

## CITATION

Vanhove B, Marot S, So RT, Gaborit B, Evanno G, Malet I, Lafrogne G, Mevel E, Ciron C, Royer P-J, Lheriteau E, Raffi F, Bruzzone R, Mok CKP, Duvaux O, Marcelin A-G and Calvez V (2023) Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants. *Front. Immunol.* 14:1208705. doi: 10.3389/fimmu.2023.1208705

## COPYRIGHT

© 2023 Vanhove, Marot, So, Gaborit, Evanno, Malet, Lafrogne, Mevel, Ciron, Royer, Lheriteau, Raffi, Bruzzone, Mok, Duvaux, Marcelin and Calvez. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants

Bernard Vanhove<sup>1\*†</sup>, Stéphane Marot<sup>2†</sup>, Ray T. So<sup>3</sup>, Benjamin Gaborit<sup>4,5</sup>, Gwénaëlle Evanno<sup>1</sup>, Isabelle Malet<sup>2</sup>, Guillaume Lafrogne<sup>1</sup>, Edwige Mevel<sup>1</sup>, Carine Ciron<sup>1</sup>, Pierre-Joseph Royer<sup>1</sup>, Elsa Lheriteau<sup>1</sup>, François Raffi<sup>4,5</sup>, Roberto Bruzzone<sup>3,6</sup>, Chris Ka Pun Mok<sup>7,8</sup>, Odile Duvaux<sup>1\*</sup>, Anne-Geneviève Marcelin<sup>2‡</sup> and Vincent Calvez<sup>2‡</sup>

<sup>1</sup>Xenothera, Nantes, France, <sup>2</sup>Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM) 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France, <sup>3</sup>Hong Kong University (HKU)-Pasteur Research Pole, School of Public Health, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China, <sup>4</sup>Department of Infectious Disease, Nantes University Hospital, Nantes, France, <sup>5</sup>Institut National de la Santé et de la Recherche Médicale (INSERM) CIC1413, Nantes University Hospital, Nantes, France, <sup>6</sup>Department of Cell Biology and Infection, Institut Pasteur, Paris, France, <sup>7</sup>Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China, <sup>8</sup>The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China

## KEYWORDS

COVID-19, polyclonal antibody (PAb), SARS-CoV-2, variants, neutralization

## A corrigendum on

**XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants**

by Vanhove B, Marot S, So RT, Gaborit B, Evanno G, Malet I, Lafrogne G, Mevel E, Ciron C, Royer P-J, Lheriteau E, Raffi F, Bruzzone R, Mok CKP, Duvaux O, Marcelin A-G and Calvez V (2021) *Front. Immunol.* 12:761250. doi: 10.3389/fimmu.2021.761250

In the published article, there was an error in the Funding statement within the Acknowledgements section (funding from the European Union was omitted). The Acknowledgments and Funding sections have now been split as well. The correct Acknowledgments and Funding statements appear below.

## Funding

This work was supported by Xenothera, the European Union's Horizon 2020 research and innovation programme (grant agreement No 962036), the Agence Nationale de la Recherche sur le SIDA et les Maladies Infectieuses Emergentes (ANRS MIE), AC43 Medical Virology and Emergen Program, the SARS-CoV-2 Program of the Faculty of Medicine of Sorbonne Université and by Bpifrance, grant «Projet de Recherche et Développement Structurant Pour la Compétitivité spécifique à la crise sanitaire COVID-19—POLYCOR» and the National Research Foundation of Korea (NRF) grant funded through the Korea government (NRF-2018M3A9H4055203).

## Acknowledgments

We sincerely thank Prof. Xavier de Lamballerie and Dr. Franck Touret from UMR IRD 190, Inserm 1207 “Unité des Virus Émergents,” Aix-Marseille Université for their active technical contribution to generating neutralization data and for their advice. We also thank the virology departments of Saint-Antoine and Avicenne University hospitals who gently shared the clinical specimen allowing us to isolate the Gamma/P.1 and Delta/B.1.617.2 variants, respectively. We also thank Prof. Jincun Zhao and Yanqun Wang for providing us the adenovirus that carries the human ACE-2.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.